Fuguhara Vivian, De Oliveira Mariana Gonçalves, Aguiar da Silva Carlos Alberto, Guazzelli Pedro Renato, Peterson Larryn W, De Nucci Gilberto
Department of Pharmacology, Faculty of Medical Science, State University of Campinas (UNICAMP), Campinas, Brazil.
Laboratory of Multidisciplinary Research, São Franscisco University (USF), Bragança Paulista, Brazil.
Front Pharmacol. 2025 May 20;16:1557997. doi: 10.3389/fphar.2025.1557997. eCollection 2025.
6-Nitrodopamine (6-ND) has been extensively investigated using in vitro protocols, especially in the cardiovascular system. Despite the established more potent positive chronotropic and inotropic effects, in comparison with the classical catecholamines, adrenaline (ADR), noradrenaline (NA) and dopamine (DA), the effects with in vivo models are not determined yet. Here, we investigated the acute effects on heart rate (HR) and mean arterial blood pressure (MABP) in normotensive and hypertensive rats by 6-ND.
Adult male Wistar rats were randomly divided into two groups: one received regular filtered water and the other a chronic Nω-nitro-L-arginine methyl ester (L-NAME) treatment in the water (20mg/day/rat, 4weeks). Thereafter, the animals were anesthetized, the HR and MABP were monitored through the femoral artery, and the vein was used to administer bolus injections of 6-ND, ADR, NA and DA. Moreover, 6-ND, classical and novel catecholamines, 6-cyanodopamine (6-CYANO), 6nitroadrenaline (6-NADR), and 6-nitrodopa (6-NDOPA) were used to assess their effect on monoamine oxidase (MAO) activity.
All four drugs significantly increased the HR in control animals; 6-ND was more potent than the classical catecholamines and its positive chronotropic effect was abolished with the chronic L-NAME treatment. Furthermore, in a cell-free assay, 6-ND was able to partially inhibit MAO-A (<30% at 1 mM) and MAO-B (<40% at 10 μM); 6-NDOPA and 6-CYANO (1 mM) inhibited MAO-A, and MAO-B by around 40%, respectively. ADR produced MAO-A inhibition of <20%, at 100μM.
These results clearly demonstrate that 6-ND is the most potent endogenous positive chronotropic agent yet described, and its effects are independent of MAO inhibition.
6-硝基多巴胺(6-ND)已通过体外实验方案进行了广泛研究,尤其是在心血管系统方面。尽管已证实与经典儿茶酚胺肾上腺素(ADR)、去甲肾上腺素(NA)和多巴胺(DA)相比,6-ND具有更强的正性变时和变力作用,但尚未确定其在体内模型中的作用效果。在此,我们研究了6-ND对正常血压和高血压大鼠心率(HR)和平均动脉血压(MABP)的急性影响。
成年雄性Wistar大鼠随机分为两组:一组给予常规过滤水,另一组给予水中慢性Nω-硝基-L-精氨酸甲酯(L-NAME)处理(20mg/天/只,共4周)。此后,将动物麻醉,通过股动脉监测HR和MABP,并通过静脉给予6-ND、ADR、NA和DA的单次注射。此外,使用6-ND、经典和新型儿茶酚胺、6-氰基多巴胺(6-CYANO)、6-硝基肾上腺素(6-NADR)和6-硝基多巴(6-NDOPA)来评估它们对单胺氧化酶(MAO)活性的影响。
所有四种药物均显著增加了对照动物的HR;6-ND比经典儿茶酚胺更有效,其正性变时作用在慢性L-NAME处理后被消除。此外,在无细胞实验中,6-ND能够部分抑制MAO-A(1 mM时<30%)和MAO-B(10 μM时<40%);6-NDOPA和6-CYANO(1 mM)分别抑制MAO-A和MAO-B约40%。ADR在100μM时对MAO-A的抑制率<20%。
这些结果清楚地表明,6-ND是迄今描述的最有效的内源性正性变时剂,其作用与MAO抑制无关。